Tifluadom is a kappa-opioid receptor agonist. It has been shown to produce antinociception in the rotarod test and locomotor activity in mice, as well as having other pharmacological effects. Tifluadom is used to treat inflammatory disorders and autoimmune diseases. The mechanism of action of Tifluadom is not fully understood, but it may be due to its ability to bind with the benzodiazepine binding site on the GABAA receptor and also activate κ-opioid receptors. Tifluadom has been shown to increase the glomerular filtration rate (GFR) in rats by activating dopaminergic receptors that are involved in renal function.